Neparvis

sacubitril / valsartan

Overview
Authorisation details
Product information
Assessment history

Authorised

This medicine is authorised for use in the European Union.

Overview

Neparvis is a heart medicine used in adults with chronic (long-term) heart failure who have symptoms of the disease and reduced ejection fraction (a measure of how well the heart pumps blood). The medicine is also used in adolescents and children from 1 year of age with chronic heart failure who have symptoms of the disease and left ventricular systolic dysfunction (a problem affecting the left side of the heart).

Heart failure is the inability of the heart to pump enough blood around the body.

Neparvis contains the active substances sacubitril and valsartan.

This medicine is the same as Entresto, which is already authorised in the EU. The company that makes Neparvis has agreed that its scientific data can be used for Neparvis (‘informed consent’).

: Neparvis can only be obtained with a prescription. The medicine is available as tablets and granules to be taken by month twice a day.
For more information about using Neparvis, see the package leaflet or contact your doctor or pharmacist.

: The two active substances in Neparvis, sacubitril and valsartan, work in different ways. Sacubitril blocks the breakdown of natriuretic peptides produced in the body. Natriuretic peptides cause sodium and water to pass into the urine thereby reducing the strain on the heart. They also reduce blood pressure and protect the heart from developing fibrosis (scar tissue) that occurs in heart failure.
Valsartan is an ‘angiotensin-II-receptor antagonist’, which means that it blocks the action of a hormone called angiotensin II. The effects of angiotensin II can be harmful in patients with heart failure. By blocking the receptors (targets) to which angiotensin II normally attaches, valsartan stops the hormone’s harmful effects on the heart and also reduces blood pressure by allowing blood vessels to widen.

: Neparvis has been shown to be effective at treating heart failure in adults in one main study. In the study, Neparvis was compared to enalapril, another medicine used for heart failure. Patients in the study had long-term heart failure with symptoms of the disease and reduced ejection fraction (the proportion of blood leaving the heart). In the group treated with Neparvis, 21.8% (914 of 4,187) of patients either died as a result of heart and circulation problems or were admitted to hospital with heart failure compared to 26.5% (1,117 of 4,212) of patients treated with enalapril. In general, patients were monitored for about 27 months, during which they took the medicine for about 24 months on average. The study was stopped early because there was compelling evidence that Neparvis was more effective than enalapril.
A study involving children and adolescents showed that the way Neparvis behaves in the body in people below 18 years old is similar to that seen in adults. In addition, Neparvis led to similar reductions across age groups in the blood levels of NT-proBNP. Patients with heart failure have raised levels of NT-proBNP, substances made by the heart. A reduced level of NT-proBNP is associated with a better outcome for patients.
In addition, the study comparing Neparvis with enalapril in 377 patients aged 1 month to below 18 years with heart failure due to systemic left ventricle systolic dysfunction. The main measure of effectiveness was the likelihood of a better outcome after one year of treatment compared with that in the other treatment group (based on the ranking of various events such as death, urgent heart transplant or worsening of symptoms). The results did not show that Neparvis was more effective than enalapril in terms of this measure. However, in both the Neparvis and enalapril groups, there were relevant improvements in symptoms and quality of life measures.

: For the full list of side effects and restrictions with Neparvis, see the package leaflet.
The most common side effects with Neparvis in adults (which may affect more than 1 in 10 people) include hyperkalaemia (high blood potassium levels), hypotension (low blood pressure) and renal impairment (kidneys working less well). A potentially severe side effect, angioedema (rapid swelling of deeper skin tissues as well as the tissues around the throat, causing breathing difficulty) can occur uncommonly (in up to 1 in 100 people).
Side effects in children and adolescents are similar to those seen in adults.
Neparvis must not be taken with medicines known as ACE inhibitors (to treat heart failure and high blood pressure) or with medicines containing aliskiren (to treat high blood pressure) in patients who have diabetes or reduced kidney function. It must not be taken by patients who have suffered angioedema, those who have severe liver disease or by women who are pregnant.

: The European Medicines Agency decided that the benefits of Neparvis are greater than its risks and it can be authorised for use in the EU. The main study found that in adults Neparvis reduced deaths from heart and circulation problems or hospital admissions for heart failure. An additional study has shown that Neparvis is expected to provide clinically meaningful benefits to children and adolescents with symptomatic heart failure due to systemic left ventricular dysfunction.
The serious side effects with Neparvis in the main study were similar to those of enalapril, another medicine used for heart failure. Valsartan, one of the active substances in the medicine, is well established for the treatment of high blood pressure and heart failure; its side effects are well known.

: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Neparvis have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Neparvis are continuously monitored. Suspected side effects reported with Neparvis are carefully evaluated and any necessary action taken to protect patients.

: Neparvis was granted a marketing authorisation valid throughout the European Union on 26 May 2016.
Further information on Neparvis can be found on the Agency’s website: ema.europa.eu/medicines/human/EPAR/neparvis.
This overview was last updated in 04-2023.

List item

Neparvis : EPAR - Summary for the public (PDF/96.57 KB)

First published: 13/06/2016
Last updated: 22/06/2023
EMA/183671/2023
- Bulgarian
  (PDF/120.88 KB)
- Croatian
  (PDF/111.91 KB)
- Czech
  (PDF/118.05 KB)
- Danish
  (PDF/97.29 KB)
- Dutch
  (PDF/98.11 KB)
- Estonian
  (PDF/96.57 KB)
- Finnish
  (PDF/97.27 KB)
- French
  (PDF/98.56 KB)
- German
  (PDF/98.43 KB)
- Greek
  (PDF/130.03 KB)
- Hungarian
  (PDF/113.13 KB)
- Italian
  (PDF/97.62 KB)
- Latvian
  (PDF/127.08 KB)
- Lithuanian
  (PDF/115.69 KB)
- Maltese
  (PDF/117.16 KB)
- Polish
  (PDF/117.58 KB)
- Portuguese
  (PDF/97.89 KB)
- Romanian
  (PDF/114.45 KB)
- Slovak
  (PDF/115.05 KB)
- Slovenian
  (PDF/112.43 KB)
- Spanish
  (PDF/97.9 KB)
- Swedish
  (PDF/97.09 KB)
List item

Neparvis : EPAR - Risk-management-plan summary (PDF/86.91 KB)

First published: 07/12/2020
Last updated: 07/09/2023

This EPAR was last updated on 13/09/2023

Authorisation details

Product details
Name	Neparvis
Agency product number	EMEA/H/C/004343
Active substance	sacubitril valsartan
International non-proprietary name (INN) or common name	sacubitril valsartan
Therapeutic area (MeSH)	Heart Failure
Anatomical therapeutic chemical (ATC) code	C09DX04
Additional monitoring	This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder	Novartis Europharm Limited
Revision	18
Date of issue of marketing authorisation valid throughout the European Union	26/05/2016
Contact address	Vista Building Elm Park, Merrion Road Dublin 4 Ireland

Product information

11/09/2023 Neparvis - EMEA/H/C/004343 - IG1654/G

List item

Neparvis : EPAR - Product Information (PDF/730.45 KB)

First published: 13/06/2016
Last updated: 13/09/2023
- Bulgarian
  (PDF/1017.99 KB)
- Croatian
  (PDF/859.12 KB)
- Czech
  (PDF/971.1 KB)
- Danish
  (PDF/714.61 KB)
- Dutch
  (PDF/784.55 KB)
- Estonian
  (PDF/722.57 KB)
- Finnish
  (PDF/733.18 KB)
- French
  (PDF/910.3 KB)
- German
  (PDF/777.54 KB)
- Greek
  (PDF/1.01 MB)
- Hungarian
  (PDF/942.71 KB)
- Icelandic
  (PDF/718.14 KB)
- Italian
  (PDF/834.47 KB)
- Latvian
  (PDF/913.38 KB)
- Lithuanian
  (PDF/945.63 KB)
- Maltese
  (PDF/1005.79 KB)
- Norwegian
  (PDF/723.99 KB)
- Polish
  (PDF/1.01 MB)
- Portuguese
  (PDF/778.62 KB)
- Romanian
  (PDF/933.64 KB)
- Slovak
  (PDF/964.5 KB)
- Slovenian
  (PDF/916.92 KB)
- Spanish
  (PDF/744.78 KB)
- Swedish
  (PDF/736.57 KB)

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

Product information documents contain:

summary of product characteristics (annex I);
manufacturing authorisation holder responsible for batch release (annex IIA);
conditions of the marketing authorisation (annex IIB);
labelling (annex IIIA);
package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

List item

Neparvis : EPAR - All Authorised presentations (PDF/93.49 KB)

First published: 13/06/2016
Last updated: 22/06/2023
- Bulgarian
  (PDF/65.81 KB)
- Croatian
  (PDF/95.94 KB)
- Czech
  (PDF/96.05 KB)
- Danish
  (PDF/95.51 KB)
- Dutch
  (PDF/93.43 KB)
- Estonian
  (PDF/92.78 KB)
- Finnish
  (PDF/93.21 KB)
- French
  (PDF/92.21 KB)
- German
  (PDF/159.9 KB)
- Greek
  (PDF/165.62 KB)
- Hungarian
  (PDF/100.35 KB)
- Icelandic
  (PDF/94.28 KB)
- Italian
  (PDF/94.07 KB)
- Latvian
  (PDF/97.63 KB)
- Lithuanian
  (PDF/162.55 KB)
- Maltese
  (PDF/97.72 KB)
- Norwegian
  (PDF/94.85 KB)
- Polish
  (PDF/97.2 KB)
- Portuguese
  (PDF/93.57 KB)
- Romanian
  (PDF/158.7 KB)
- Slovak
  (PDF/97.73 KB)
- Slovenian
  (PDF/159.15 KB)
- Spanish
  (PDF/156.72 KB)
- Swedish
  (PDF/93.63 KB)

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Paediatric heart failure

Neparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).

Adult heart failure

Neparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1).

Assessment history

Changes since initial authorisation of medicine

List item

Neparvis : EPAR - Procedural steps taken and scientific information after authorisation (PDF/2.36 MB)

First published: 05/10/2016
Last updated: 13/09/2023
List item

Neparvis : EPAR - Paediatric investigation plan compliance statement (PDF/95.83 KB)

First published: 22/06/2023
EMA/286177/2023
List item

Neparvis-H-C-4343-X-0042 : EPAR - Assessment Report – Extension (PDF/3.74 MB)

Adopted

First published: 22/06/2023
EMA/172237/2023
List item

CHMP post-authorisation summary of positive opinion for Neparvis (X-42-G) (PDF/89.18 KB)

Adopted

First published: 31/03/2023
EMA/CHMP/130048/2023
List item

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines (PDF/119.28 KB)

Adopted

First published: 05/07/2021
- Bulgarian
  (PDF/145.18 KB)
- Croatian
  (PDF/142.87 KB)
- Czech
  (PDF/139.02 KB)
- Danish
  (PDF/126.81 KB)
- Dutch
  (PDF/127.53 KB)
- Estonian
  (PDF/123.85 KB)
- Finnish
  (PDF/125.84 KB)
- French
  (PDF/127.12 KB)
- German
  (PDF/131.05 KB)
- Greek
  (PDF/139.5 KB)
- Hungarian
  (PDF/137.17 KB)
- Italian
  (PDF/126.56 KB)
- Latvian
  (PDF/147.7 KB)
- Lithuanian
  (PDF/148.34 KB)
- Maltese
  (PDF/151.21 KB)
- Polish
  (PDF/137.7 KB)
- Portuguese
  (PDF/128.87 KB)
- Romanian
  (PDF/143.59 KB)
- Slovak
  (PDF/135.07 KB)
- Slovenian
  (PDF/149.74 KB)
- Spanish
  (PDF/125.85 KB)
- Swedish
  (PDF/126.99 KB)
List item

Neparvis : EPAR - EMEA/H/C/PSUSA/00010438/202007 - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/119.1 KB)

First published: 11/06/2021
Last updated: 11/06/2021
List item

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines (PDF/362.31 KB)

Adopted

First published: 02/03/2021
EMA/47245/2021
List item

Neparvis-H-C-4343-A31-0020 : EPAR - Scientific conclusions (PDF/99.42 KB)

First published: 21/05/2019
- Bulgarian
  (PDF/136.15 KB)
- Croatian
  (PDF/125.02 KB)
- Czech
  (PDF/131.08 KB)
- Danish
  (PDF/96.12 KB)
- Dutch
  (PDF/99.3 KB)
- Estonian
  (PDF/94.4 KB)
- Finnish
  (PDF/97.12 KB)
- French
  (PDF/97.56 KB)
- German
  (PDF/100.2 KB)
- Greek
  (PDF/142.79 KB)
- Hungarian
  (PDF/119.82 KB)
- Italian
  (PDF/95.54 KB)
- Latvian
  (PDF/130.68 KB)
- Lithuanian
  (PDF/130.84 KB)
- Maltese
  (PDF/133.78 KB)
- Polish
  (PDF/130.65 KB)
- Portuguese
  (PDF/96.47 KB)
- Romanian
  (PDF/128.25 KB)
- Slovak
  (PDF/119.14 KB)
- Slovenian
  (PDF/124.14 KB)
- Spanish
  (PDF/98.31 KB)
- Swedish
  (PDF/96.85 KB)
List item

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report (PDF/531.32 KB)

Adopted

First published: 02/05/2019
EMA/217823/2019

Neparvis

Table of contents

Overview

Neparvis : EPAR - Summary for the public (PDF/96.57 KB)

Neparvis : EPAR - Risk-management-plan summary (PDF/86.91 KB)

Authorisation details

Product information

Neparvis : EPAR - Product Information (PDF/730.45 KB)

Neparvis : EPAR - All Authorised presentations (PDF/93.49 KB)

Pharmacotherapeutic group

Therapeutic indication

Assessment history

Changes since initial authorisation of medicine

Neparvis : EPAR - Procedural steps taken and scientific information after authorisation (PDF/2.36 MB)

Neparvis : EPAR - Paediatric investigation plan compliance statement (PDF/95.83 KB)

Neparvis-H-C-4343-X-0042 : EPAR - Assessment Report – Extension (PDF/3.74 MB)

CHMP post-authorisation summary of positive opinion for Neparvis (X-42-G) (PDF/89.18 KB)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines (PDF/119.28 KB)

Neparvis : EPAR - EMEA/H/C/PSUSA/00010438/202007 - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s) (PDF/119.1 KB)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines (PDF/362.31 KB)

Neparvis-H-C-4343-A31-0020 : EPAR - Scientific conclusions (PDF/99.42 KB)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report (PDF/531.32 KB)

Initial marketing-authorisation documents

Neparvis : EPAR - Public assessment report (PDF/228.47 KB)

CHMP summary of opinion for Neparvis (PDF/67.89 KB)

News

More information on Neparvis

Related content

How useful was this page?